12.19
0.07 (0.54%)
| Penutupan Terdahulu | 12.12 |
| Buka | 12.11 |
| Jumlah Dagangan | 801,711 |
| Purata Dagangan (3B) | 3,333,130 |
| Modal Pasaran | 1,576,590,336 |
| Harga / Jualan (P/S) | 2.16 |
| Harga / Buku (P/B) | 1.86 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | -11.54% |
| Margin Operasi (TTM) | -16.56% |
| EPS Cair (TTM) | -0.610 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 68.08% |
| Nisbah Semasa (MRQ) | 2.05 |
| Aliran Tunai Operasi (OCF TTM) | 7.61 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.21 M |
| Pulangan Atas Aset (ROA TTM) | -2.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | NeoGenomics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.30 |
|
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.19% |
| % Dimiliki oleh Institusi | 98.21% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| First Light Asset Management, Llc | 30 Sep 2025 | 9,927,269 |
| Julat 52 Minggu | ||
| Median | 12.00 (-1.52%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| TD Cowen | 12 Sep 2025 | 12.00 (-1.52%) | Beli | 7.96 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| OLIVO ALICIA C | - | 12.34 | -20,916 | -258,103 |
| Jumlah Keseluruhan Kuantiti Bersih | -20,916 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -258,103 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 12.34 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| OLIVO ALICIA C | Pegawai | 25 Nov 2025 | Jual automatik (-) | 20,916 | 12.34 | 258,103 |
| OLIVO ALICIA C | Pegawai | 25 Nov 2025 | Pelaksanaan pilihan | 8,977 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Nov 2025 | Pengumuman | NeoGenomics to Participate in Upcoming Investor Conferences |
| 30 Oct 2025 | Pengumuman | NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors |
| 28 Oct 2025 | Pengumuman | NeoGenomics Reports Third Quarter 2025 Results |
| 14 Oct 2025 | Pengumuman | NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025 |
| 07 Oct 2025 | Pengumuman | NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |